| Popis: |
Current therapy for acute myelogenous leukemia (AML) includes induction with Ara-C and an anthracycline, such as daunorubicin, idarubicin, or mitoxantrone. Unfortunately, most patients relapse from initial remission. Nearly one-fifth of early relapses experience treatment-related deaths. In addition, patients refractory to Ara-C die within months. Hence, new therapeutic agents must be identified capable of enhanced remission rates, diminished treatment-related mortality, or that can achieve remissions in refractory patients. |
